Fresenius SE & CO. KGAA Detailed Consensus >> Segments
Consensus as of: 2024-04-16

Please kindly note:

  1. We exclude Eugin fertility services segment. The divesture was completed on 31st of January 2024.
  2. Fresenius Medical Care is now accounted for at equity under IAS 28 in the line “Result from FME (FY 2024+: Result from Equity Method FME; 32% of FME net income before special items)”. FY 23 Actuals in the same line reflect the net income from FME operations deconsolidated under IFRS 5.
  3. Consensus estimates are before special items.

KPI[EUR m]FY 2023FY 2024 E
Fresenius Kabi, revenueNumber of Estimates7
Fresenius Kabi, revenueHighest8,569.0
Fresenius Kabi, revenueConsensus (Mean)8,009.08,452.9
Fresenius Kabi, revenueMedian8,429.0
Fresenius Kabi, revenueLowest8,365.9
Fresenius Kabi, organic revenue growth (in %)Number of Estimates7
Fresenius Kabi, organic revenue growth (in %)Highest6.2
Fresenius Kabi, organic revenue growth (in %)Consensus (Mean)7.05.5
Fresenius Kabi, organic revenue growth (in %)Median5.3
Fresenius Kabi, organic revenue growth (in %)Lowest5.1
thereof Medtech, revenueNumber of Estimates6
thereof Medtech, revenueHighest1,644.2
thereof Medtech, revenueConsensus (Mean)1,510.01,611.2
thereof Medtech, revenueMedian1,611.9
thereof Medtech, revenueLowest1,574.7
thereof Nutrition, revenueNumber of Estimates6
thereof Nutrition, revenueHighest2,460.3
thereof Nutrition, revenueConsensus (Mean)2,304.02,421.1
thereof Nutrition, revenueMedian2,422.9
thereof Nutrition, revenueLowest2,373.1
thereof Biopharma, revenueNumber of Estimates6
thereof Biopharma, revenueHighest512.6
thereof Biopharma, revenueConsensus (Mean)363.0483.0
thereof Biopharma, revenueMedian480.8
thereof Biopharma, revenueLowest445.7
Subtotal Growth Vectors, revenueNumber of Estimates6
Subtotal Growth Vectors, revenueHighest4,558.2
Subtotal Growth Vectors, revenueConsensus (Mean)4,177.04,515.3
Subtotal Growth Vectors, revenueMedian4,532.2
Subtotal Growth Vectors, revenueLowest4,438.1
Pharma (IV Drugs & Fluids), revenueNumber of Estimates6
Pharma (IV Drugs & Fluids), revenueHighest3,948.4
Pharma (IV Drugs & Fluids), revenueConsensus (Mean)3,832.03,931.0
Pharma (IV Drugs & Fluids), revenueMedian3,933.3
Pharma (IV Drugs & Fluids), revenueLowest3,900.2
Fresenius Kabi, EBITNumber of Estimates7
Fresenius Kabi, EBITHighest1,309.0
Fresenius Kabi, EBITConsensus (Mean)1,145.01,266.1
Fresenius Kabi, EBITMedian1,267.2
Fresenius Kabi, EBITLowest1,236.1
Fresenius Kabi, EBIT marginNumber of Estimates7
Fresenius Kabi, EBIT marginHighest15.3
Fresenius Kabi, EBIT marginConsensus (Mean)14.315.0
Fresenius Kabi, EBIT marginMedian15.0
Fresenius Kabi, EBIT marginLowest14.6
thereof Growth Vectors, EBITNumber of Estimates6
thereof Growth Vectors, EBITHighest563.6
thereof Growth Vectors, EBITConsensus (Mean)390.0489.0
thereof Growth Vectors, EBITMedian480.9
thereof Growth Vectors, EBITLowest434.9
thereof Growth Vectors, EBIT margin (in %)Number of Estimates6
thereof Growth Vectors, EBIT margin (in %)Highest12.5
thereof Growth Vectors, EBIT margin (in %)Consensus (Mean)9.310.8
thereof Growth Vectors, EBIT margin (in %)Median10.6
thereof Growth Vectors, EBIT margin (in %)Lowest9.8
thereof Pharma (IV Drugs & Fluids), EBIT Number of Estimates6
thereof Pharma (IV Drugs & Fluids), EBIT Highest833.3
thereof Pharma (IV Drugs & Fluids), EBIT Consensus (Mean)792.0808.9
thereof Pharma (IV Drugs & Fluids), EBIT Median809.4
thereof Pharma (IV Drugs & Fluids), EBIT Lowest784.7
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %)Number of Estimates6
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %)Highest21.2
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %)Consensus (Mean)20.720.6
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %)Median20.6
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %)Lowest19.9
thereof Corporate, EBITNumber of Estimates6
thereof Corporate, EBITHighest0.0
thereof Corporate, EBITConsensus (Mean)-37.0-37.8
thereof Corporate, EBITMedian-37.6
thereof Corporate, EBITLowest-84.3
Fresenius Helios, revenueNumber of Estimates7
Fresenius Helios, revenueHighest12,670.0
Fresenius Helios, revenueConsensus (Mean)12,320.012,513.2
Fresenius Helios, revenueMedian12,526.1
Fresenius Helios, revenueLowest12,397.0
Fresenius Helios, organic revenue growth (in %)Number of Estimates6
Fresenius Helios, organic revenue growth (in %)Highest4.8
Fresenius Helios, organic revenue growth (in %)Consensus (Mean)5.03.5
Fresenius Helios, organic revenue growth (in %)Median3.9
Fresenius Helios, organic revenue growth (in %)Lowest1.2
Helios Germany, revenueNumber of Estimates6
Helios Germany, revenueHighest7,609.1
Helios Germany, revenueConsensus (Mean)7,279.07,557.9
Helios Germany, revenueMedian7,553.8
Helios Germany, revenueLowest7,497.4
Helios Spain, revenueNumber of Estimates6
Helios Spain, revenueHighest5,034.5
Helios Spain, revenueConsensus (Mean)4,770.04,945.9
Helios Spain, revenueMedian4,946.5
Helios Spain, revenueLowest4,860.6
Fresenius Helios, EBITNumber of Estimates7
Fresenius Helios, EBITHighest1,309.0
Fresenius Helios, EBITConsensus (Mean)1,232.01,267.8
Fresenius Helios, EBITMedian1,264.8
Fresenius Helios, EBITLowest1,233.6
Fresenius Helios, EBIT margin (in %)Number of Estimates7
Fresenius Helios, EBIT margin (in %)Highest10.3
Fresenius Helios, EBIT margin (in %)Consensus (Mean)10.010.1
Fresenius Helios, EBIT margin (in %)Median10.1
Fresenius Helios, EBIT margin (in %)Lowest10.0
Helios Germany, EBITNumber of Estimates6
Helios Germany, EBITHighest677.7
Helios Germany, EBITConsensus (Mean)630.0659.5
Helios Germany, EBITMedian659.8
Helios Germany, EBITLowest645.3
Helios Spain, EBITNumber of Estimates6
Helios Spain, EBITHighest618.0
Helios Spain, EBITConsensus (Mean)580.0601.9
Helios Spain, EBITMedian604.7
Helios Spain, EBITLowest583.2
Helios Corporate, EBITNumber of Estimates5
Helios Corporate, EBITHighest-4.0
Helios Corporate, EBITConsensus (Mean)-4.0-4.3
Helios Corporate, EBITMedian-4.2
Helios Corporate, EBITLowest-5.0
Fresenius Vamed, revenueNumber of Estimates6
Fresenius Vamed, revenueHighest2,440.0
Fresenius Vamed, revenueConsensus (Mean)2,356.02,339.1
Fresenius Vamed, revenueMedian2,318.7
Fresenius Vamed, revenueLowest2,312.3
Fresenius Vamed, organic revenue growth (in %)Number of Estimates7
Fresenius Vamed, organic revenue growth (in %)Highest5.1
Fresenius Vamed, organic revenue growth (in %)Consensus (Mean)1.02.8
Fresenius Vamed, organic revenue growth (in %)Median4.0
Fresenius Vamed, organic revenue growth (in %)Lowest-1.8
Fresenius Vamed, EBITNumber of Estimates7
Fresenius Vamed, EBITHighest81.2
Fresenius Vamed, EBITConsensus (Mean)-16.061.4
Fresenius Vamed, EBITMedian58.0
Fresenius Vamed, EBITLowest48.0
Fresenius Vamed, EBIT margin (in %)Number of Estimates7
Fresenius Vamed, EBIT margin (in %)Highest3.5
Fresenius Vamed, EBIT margin (in %)Consensus (Mean)-0.72.6
Fresenius Vamed, EBIT margin (in %)Median2.5
Fresenius Vamed, EBIT margin (in %)Lowest2.0
Corporate/Other, revenueNumber of Estimates7
Corporate/Other, revenueHighest-296.6
Corporate/Other, revenueConsensus (Mean)-386.0-383.1
Corporate/Other, revenueMedian-400.0
Corporate/Other, revenueLowest-405.3
Corporate/Other, EBITNumber of Estimates7
Corporate/Other, EBITHighest-95.0
Corporate/Other, EBITConsensus (Mean)-99.0-160.9
Corporate/Other, EBITMedian-175.0
Corporate/Other, EBITLowest-185.0
Disclaimer

This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.